Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial

B.E. Peterson, D.L. Bhatt*, P.G. Steg, J. Oldgren, M. Maeng, U. Zeymer, S. Halvorsen, S.H. Hohnloser, G.Y.H. Lip, T. Kimura, M. Nordaby, C. Miede, E. Kleine, J.M. Ten Berg, C.P. Cannon, RE-DUAL PCI Steering Committee and Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)

Abstract

OBJECTIVES The aim of this study was to explore the early versus late benefits and risks of dabigatran dual therapy versus warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabi-gatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial.

BACKGROUND Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk for both bleeding and thrombotic events.

METHODS A total of 2,725 patients with atrial fibrillation underwent percutaneous coronary intervention and were randomized to receive dabigatran 110 mg, or dabigatran 150 mg plus a P2Y(12) inhibitor (and no aspirin), or warfarin plus a P2Y(12) inhibitor plus aspirin. Landmark analysis was performed at 30 and 90 days.

RESULTS There was a consistent and large reduction in major or clinically relevant nonmajor bleeding in patients randomized to dual therapy during the first 30 days (110 mg: hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.31 to 0.66; p < 0.0001; 150 mg: HR: 0.46; 95% CI: 0.30 to 0.72; p = 0.0006) compared with warfarin triple therapy. There was early net clinical benefit in both dabigatran groups versus warfarin (110 mg: HR: 0.65; 95% CI: 0.47 to 0.88; p = 0.0062; 150 mg: HR: 0.54; 95% CI: 0.37 to 0.79; p = 0.0015), due to larger reductions in bleeding than increased thrombotic events for dabigatran 110 mg and bleeding reduction without increased thrombotic risk for dabigatran 150 mg dual therapy versus warfarin triple therapy. After the removal of aspirin in the warfarin group, bleeding remained lower with dabigatran 110 mg and was similar with dabigatran 150 mg versus warfarin.

CONCLUSIONS In RE-DUAL PCI, in which patients in the dual-therapy arms were treated with aspirin for an average of only 1.6 days, there was early net clinical benefit with both doses of dabigatran dual therapy, without an increase in thrombotic events with dabigatran 150 mg. This could be helpful in the subset of patients with elevated risk for both bleeding and thrombotic events. (c) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Original languageEnglish
Pages (from-to)768-780
Number of pages13
JournalJacc-Cardiovascular Interventions
Volume14
Issue number7
DOIs
Publication statusPublished - 12 Apr 2021

Keywords

  • ANTITHROMBOTIC THERAPY
  • ASPIRIN
  • CARDIOVASCULAR OUTCOMES
  • EVENTS
  • MANAGEMENT
  • NONVALVULAR ATRIAL-FIBRILLATION
  • ORAL ANTICOAGULATION
  • PERCUTANEOUS CORONARY INTERVENTION
  • RIVAROXABAN
  • WARFARIN
  • anticoagulation
  • antiplatelet therapy
  • atrial fibrillation
  • percutaneous coronary intervention
  • DABIGATRAN

Cite this